AngioGenex, Inc. Stock price

Equities

AGGX

US03475U3014

Biotechnology & Medical Research

Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for AngioGenex, Inc. -.--% -99.85%
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 71 17-11-27
Founder 64 99-03-30
Director of Finance/CFO 57 98-12-31
Members of the board TitleAgeSince
Founder 64 99-03-30
Director/Board Member 68 20-06-29
Director of Finance/CFO 57 98-12-31
More insiders
AngioGenex, Inc. is a biopharmaceutical company, which is engaged in discovering and development of Id protein inhibitors to address unmet medical needs in oncology and ophthalmology. The Company and its collaborators, including Robert Benezra, Ph.D. and The Robert Benezra Lab at Sloan Kettering Institute, have assembled key platform enabling technologies and tools that allow for the identification of specific and potent small molecule binders of Id. Its Anti-Id platform gave rise to AGX-A, an investigational small molecule designed to selectively bind to Id proteins, thereby targeting them for degradation and reducing resulting tumor growth and neovascularization. The Company's lead development candidate is AGX-A, a small molecule being investigated for the treatment of cholangiocarcinoma and age-related macular degeneration (AMD).
More about the company
  1. Stock
  2. Equities
  3. Stock AngioGenex, Inc. - OTC Markets